PRLD Relative Valuation
PRLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRLD is overvalued; if below, it's undervalued.
Historical Valuation
Prelude Therapeutics Inc (PRLD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.08. The fair price of Prelude Therapeutics Inc (PRLD) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.54
Fair
-1.50
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Prelude Therapeutics Inc. (PRLD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.92. The thresholds are as follows: Strongly Undervalued below -16.85, Undervalued between -16.85 and -9.89, Fairly Valued between 4.04 and -9.89, Overvalued between 4.04 and 11.00, and Strongly Overvalued above 11.00. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-15.66
EV/EBIT
Prelude Therapeutics Inc. (PRLD) has a current EV/EBIT of -15.66. The 5-year average EV/EBIT is -3.43. The thresholds are as follows: Strongly Undervalued below -18.14, Undervalued between -18.14 and -10.79, Fairly Valued between 3.93 and -10.79, Overvalued between 3.93 and 11.28, and Strongly Overvalued above 11.28. The current Forward EV/EBIT of -15.66 falls within the Undervalued range.
2.11
PS
Prelude Therapeutics Inc. (PRLD) has a current PS of 2.11. The 5-year average PS is 0.09. The thresholds are as follows: Strongly Undervalued below -0.91, Undervalued between -0.91 and -0.41, Fairly Valued between 0.59 and -0.41, Overvalued between 0.59 and 1.09, and Strongly Overvalued above 1.09. The current Forward PS of 2.11 falls within the Strongly Overvalued range.
0.00
P/OCF
Prelude Therapeutics Inc. (PRLD) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.49. The thresholds are as follows: Strongly Undervalued below -23.66, Undervalued between -23.66 and -14.08, Fairly Valued between 5.10 and -14.08, Overvalued between 5.10 and 14.68, and Strongly Overvalued above 14.68. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
454.83
P/FCF
Prelude Therapeutics Inc. (PRLD) has a current P/FCF of 454.83. The 5-year average P/FCF is 16.33. The thresholds are as follows: Strongly Undervalued below -171.34, Undervalued between -171.34 and -77.50, Fairly Valued between 110.17 and -77.50, Overvalued between 110.17 and 204.01, and Strongly Overvalued above 204.01. The current Forward P/FCF of 454.83 falls within the Strongly Overvalued range.
Prelude Therapeutics Inc (PRLD) has a current Price-to-Book (P/B) ratio of 2.00. Compared to its 3-year average P/B ratio of 0.98 , the current P/B ratio is approximately 103.80% higher. Relative to its 5-year average P/B ratio of 2.26, the current P/B ratio is about -11.29% higher. Prelude Therapeutics Inc (PRLD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -95.99%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -63.66% , the current FCF yield is about -100.00% lower.
2.00
P/B
Median3y
0.98
Median5y
2.26
-88.19
FCF Yield
Median3y
-95.99
Median5y
-63.66
Competitors Valuation Multiple
The average P/S ratio for PRLD's competitors is 0.00, providing a benchmark for relative valuation. Prelude Therapeutics Inc Corp (PRLD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 116.67%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRLD increased by 20.78% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.00M to 6.50M.
The secondary factor is the P/E Change, contributed -24.10%to the performance.
Overall, the performance of PRLD in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Prelude Therapeutics Inc (PRLD) currently overvalued or undervalued?
What is Prelude Therapeutics Inc (PRLD) fair value?
How does PRLD's valuation metrics compare to the industry average?
What is the current P/B ratio for Prelude Therapeutics Inc (PRLD) as of Dec 05 2025?
What is the current FCF Yield for Prelude Therapeutics Inc (PRLD) as of Dec 05 2025?
What is the current Forward P/E ratio for Prelude Therapeutics Inc (PRLD) as of Dec 05 2025?